Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

GBA Gene Gaucher Disease Type 3C Genetic Test in UAE | 2800 AED | DHA Licensed

Executive Summary & Core Metrics

Core Metrics

  • Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 accredited processing and NGS full-gene coverage.
  • Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
  • Clinical Guidance: Telephonic Post-Test Clinical Guidance by DHA-licensed specialists for result interpretation.
  • Insurance & Billing Verification: Direct coordination via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The GBA Gene Gaucher Disease Type 3C Genetic Test utilises Next Generation Sequencing (NGS) to empower clinicians with precise genotypic data, guiding enzyme replacement or substrate reduction therapies and long‑term surveillance for malignancy risk.

Feature Our Test (ISO 15189) Closest Alternative (Standard Enzyme Assay)
Precision Full gene sequencing with variant‑level resolution Indirect activity measurement; cannot identify mutation type
Methodology NGS (Next Generation Sequencing) Fluorometric enzyme assay
Turnaround Time 3–4 Weeks 1–2 Weeks
Diagnostic Weight Confirms carrier status, subtype classification, and prognostic markers Only indicates deficient enzyme activity; inconclusive for carrier detection

Physician Insight & Safety Protocols

Insight from Consultant Medical Genetics

“An NGS result for the GBA gene must never be interpreted in isolation. Clinical correlation with neurological examination, haematological parameters, and family pedigree is essential. A positive variant informs risk and guides therapy, but only a comprehensive specialist evaluation can determine the optimal care pathway. At DNA Labs UAE, we ensure that each report is reviewed by both a clinical geneticist and a biochemical specialist.”

— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403

⚠️ Safety Advisory: Medication Continuity

Do not discontinue prescribed enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) without consulting your treating specialist. Any modification must be supervised by your physician.

⛔ Exclusion Criteria & Emergency Red Flags

  • Not indicated for asymptomatic minors without informed consent from a legal guardian.
  • Patients with acute psychiatric instability or inability to understand genetic counselling implications.
  • Any severe intercurrent infection requiring hospitalisation – postpone collection.

🚨 Urgent Red Flags (seek immediate medical help):

  • Sudden severe bone pain or pathological fracture.
  • New‑onset seizures or progressive neurological deterioration.
  • Unexplained bleeding or easy bruising.
  • Acute abdominal distension or severe fatigue.

Patient FAQ & Clinical Guidance

1. What is the GBA gene Gaucher disease type 3C NGS test?

This advanced genetic test sequences the entire GBA gene to identify mutations responsible for Gaucher disease type 3C, a chronic neuronopathic lysosomal storage disorder. It provides definitive molecular confirmation, differentiates it from other metabolic conditions, and helps forecast the disease course. The result enables targeted management, including enzyme replacement and regular monitoring for haematological and neurological complications.

2. How is the sample collected, and is home collection available?

Samples are collected via painless venipuncture (EDTA blood), extracted DNA, or a single drop on an FTA card. VIP home collection by licensed phlebotomists is available across all UAE emirates with ISO‑certified cold‑chain transport. Our home service operates daily from 8 AM to 11 PM, ensuring comfort and privacy. Once collected, the specimen is immediately preserved and transported under temperature‑controlled conditions to our DHA‑licensed molecular laboratory.

3. When will I receive results and what do they mean?

Results are delivered within 3 to 4 weeks and include a telephonic clinical guidance session with a DHA‑licensed specialist who explains variant pathogenicity and recommends follow‑up with a clinical geneticist or metabolic expert. The report will categorise identified variants as benign, likely benign, variant of uncertain significance, likely pathogenic, or pathogenic. A pathogenic finding confirms Gaucher disease type 3C, guiding immediate therapeutic decisions. Indeterminate results may require family segregation studies.

UAE Regulatory & Data Privacy Adherence

Compliance Framework

All personal and health data processed during the GBA Genetic Test are handled in strict adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. The laboratory operates under DHA Facility License Number 1143 and complies with Federal Decree-Law No. 4 of 2016 on Medical Liability for clinical safety and patient consent. Your information is encrypted, access‑controlled, and never shared without explicit consent.

Clinical & Logistical Metadata

Test Name GBA Gene Gaucher Disease Type 3C Genetic Test
Price (AED) 2,800 AED
Turnaround Time 3–4 Weeks
Sample Type / Matrix Peripheral whole blood (EDTA), extracted DNA, or FTA card
Methodology Used Next Generation Sequencing (NGS) – full GBA gene coverage
ICD-10-CM Code E75.22
LOINC Code 61694-1
DHA Facility License & Laboratory Address License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
Corporate Lab: DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians